Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Optiscan Imaging Limited ( (AU:OIL) ) has issued an update.
Optiscan Imaging Limited has launched a pioneering clinical study at the Royal Melbourne Hospital to evaluate surgical margins in breast cancer treatment using its InVue® and InForm™ imaging devices. This study, involving 50 patients, aims to demonstrate the real-time imaging capabilities of these devices, potentially reducing reliance on post-operative pathology and improving surgical precision. The data collected will support US FDA regulatory submissions and contribute to the development of AI/ML algorithms. The study underscores Optiscan’s commitment to advancing breast cancer treatment by integrating advanced imaging technology into surgical workflows, potentially setting a new standard for precision and efficiency in the field.
More about Optiscan Imaging Limited
Optiscan Imaging Limited is a company operating in the medical imaging industry, specializing in precision surgery imaging devices. Their primary products include the InVue® precision surgery imaging device for in vivo imaging and the InForm™ digital pathology imaging device for ex vivo imaging. The company focuses on enhancing surgical procedures and diagnostics, particularly in the field of cancer treatment.
Average Trading Volume: 133,384
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$83.53M
See more data about OIL stock on TipRanks’ Stock Analysis page.